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Context:  Patients with adrenocortical carcinoma (ACC) often fail mitotane treatment and 
deal with severe toxicity, marking the relevance of predictive parameters for treatment 
outcome. 
Objective:  Determine the effects of mitotane in primary ACC cultures, and correlate sensitivity 
with patient and tumor characteristics. 
Methods:  In 32 primary ACC cultures, the effects of mitotane on cell growth and cortisol 
production were determined. RRM1, SOAT1, and CYP2W1 expression were assessed using 
reverse transcription-polymerase chain reaction and immunohistochemistry. 
Results:  The median percentage cell amount inhibition in primary ACC cultures at 
50 µM mitotane was 57%. Seven patients were classified as nonresponders, 14 as partial 
responders, and 11 as responders. The mean median effective concentration (EC50) 
value of mitotane for inhibition of cell amount in responders was 14.2 µM (95% CI, 
11.3–17.9), in partial responders 41.6 µM (95% CI, 33.5–51.8), and could not be calculated 
in nonresponders. The percentage cortisol-producing ACC was 14%, 43%, and 73% for 
nonresponders, partial responders, and responders (P = 0.068). Mitotane inhibited cortisol 
production with a mean EC50 of 1.4 µM (95% CI, 0.9–2.1), which was considerably lower than 
the EC50 on cell growth. RRM1, SOAT1, and CYP2W1 expression levels were not predictive 
for mitotane sensitivity in vitro.
Conclusion:  Direct antitumor effects of mitotane on human primary ACC cultures are highly 
variable between patients, reflecting heterogeneous responses in patients. Cortisol was 
inhibited at lower concentrations, compared with its effect on cell amount. Cortisol secretion by 
ACC might be associated with enhanced mitotane sensitivity due to increased direct antitumor 
effects of mitotane. (J Clin Endocrinol Metab 105: 1–11, 2020)
A drenocortical carcinoma (ACC) is a rare ma-lignancy with 5-year survival rates of 16–44% 
(1–3). Although surgery is the only curative treat-
ment modality, medical therapy can be used in meta-
static disease or to prevent recurrences after radical 
ACC resection (4). Mitotane is the only accepted 
adrenolytic drug, but response rates and efficacy in 
both the above-mentioned settings are limited (5), 
and mitotane use is accompanied by severe adverse 
effects.
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Abbreviations: ACA, adrenocortical adenoma; ACC, adrenocortical carcinoma; DFS, 
disease-free survival; NA, normal adrenal; PCR, polymerase chain reaction.
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Markers that predict which patients benefit from 
mitotane treatment are of great importance in order to 
prevent overtreatment and adverse effects, as well as to 
safe on costs. Reaching the target plasma concentration 
of 14  mg/L (~50 μM) is currently considered the most 
important predictive marker for response to mitotane, 
with fewer recurrences and a longer disease-free survival 
(DFS) in patients who reach this plasma concentration 
(1, 6, 7). In a recent report, it was shown that particu-
larly patients in which mitotane was initiated at late re-
currences and patients with low tumor grade responded 
to mitotane (8). Volante et  al. showed a correlation of 
expression of ribonucleotide reductase large subunit 
(RRM1) with DFS and overall survival in ACC patients 
(9). In patients with low tumoral RRM1 expression, a sig-
nificantly longer DFS was found in patients who received 
adjuvant mitotane than in patients who were only moni-
tored during follow-up. This difference was not present in 
patients with high RRM1 expression (9). As a possible ex-
planatory mechanism, Germano et al. showed that RRM1 
interferes with mitotane metabolism and bioavailability 
of the active metabolite in ACC cell line models in vitro 
(10). Recently, Sterol-O-Acyl-Transferase 1 (SOAT1) was 
identified as a key molecular target for mitotane, which 
expression was positively correlated with a longer time 
to progression and DFS in patients treated with mitotane 
(11). In another study, CYP2W1 immunoreactivity, ad-
justed for European Network for the Study of Adrenal 
Tumors (ENSAT) stage, was positively associated with 
a longer overall survival and time to progression in pa-
tients treated with mitotane (12). CYP2W1 is considered 
an orphan human cytochrome P450 enzyme, because its 
physiologic substrate is still unknown. Expression of this 
enzyme is known to be high during fetal life and in some 
cancers, and has recently gained attention as a promising 
tool in targeted therapy (13). Other factors in ACC have 
particularly been associated with diagnosis of ACC, as 
well as prognosis and progress (5, 14–16). In this study, 
however, we focus on markers that might correlate with 
mitotane sensitivity and not prognosis.
The objective of this study was to assess for the first 
time the direct effects of mitotane on cell growth and cor-
tisol production in a large series of primary human ACC 
cultures. Furthermore, we aimed to evaluate the relation-
ship between mitotane sensitivity and clinical and tumor 
characteristics, and the previously proposed potential 
predictive parameters RRM1, SOAT1, and CYP2W1.
Materials and Methods
Patients and tissue samples
ACCs, adrenocortical adenomas (ACAs), and normal ad-
renals (NAs) were collected during surgeries performed at 
the Department of Surgery at the Erasmus MC between June 
1990 and August 2016. Diagnosis was made on the basis of 
the Van Slooten Index (VSI) or the Weiss score (WS) (17, 18), 
dependent on the year of pathologic diagnosis. Normal ad-
renals were collected during nephrectomy and confirmed by 
the pathologist as being normal. The following clinical param-
eters were obtained from all ACC and ACA patients: age at 
diagnosis, follow-up time, sex, tumor size, ENSAT stage in 
case of primary tumors, hormonal secretion status, systemic 
therapies received prior to surgery, and development of me-
tastases. A  part of the tissue specimens was embedded in 
Tissue-Tek directly after resection and stored at –80°C until 
analysis. Another part was processed to obtain primary cul-
tures and to isolate total RNA, as described below. In vivo 
cortisol production was identified by an increased urinary free 
cortisol, increased midnight salivary cortisol level, a positive 
dexamethasone suppression test, or a combination of tests. 
Informed consent was obtained from all patients. The study 
was conducted under the guidelines that had been approved 
by the Medical Ethics Committee of the Erasmus Medical 
Center.
Primary cultures
Immediately after surgery, a part of the ACC specimen was 
minced into small pieces of 2–3 mm3, washed in culture me-
dium and centrifuged for 5 minutes at 600 g. The culture me-
dium consisted of DMEM-F12 (Fisher Scientific, Landsmeer, 
The Netherlands) containing 5% fetal calf serum (FCS), 
penicillin (1 × 105 U/; Bristol-Meyers Squibb, Woerden, The 
Netherlands) and l-glutamine (2  mmol/L; Fisher Scientific, 
Landsmeer, the Netherlands). The remaining tissue pellet 
was suspended in culture medium and was stored over-
night at 4°C, whereafter the tissue was centrifuged again 
and the supernatant was removed. Tissues were dissociated 
in 10–25 mL of medium with collagenase type-I (2 mg/mL; 
Sigma-Aldrich, Zwijndrecht, The Netherlands) by incuba-
tion at 37°C for up to 2 hours. If necessary, the obtained 
suspension was filtered through a sterile needle. Ficoll (GE 
Healthcare, Eindhoven, The Netherlands) density gradient 
separation was used once or twice in order to separate 
contaminating red blood cells from the tumor cells. After 
centrifugation for 20 minutes at 600 g, the interphase con-
taining the tumor cells was collected. Trypan blue exclu-
sion was used to determine cell viability, and adrenal cells 
were visually counted using Türk solution. Dissociated cells 
were plated in quadruplicate at a density of 105 cells per 
well in a 24-well plate in 1 mL of culture medium. Medium 
was refreshed after 3–4 days and incubations with mitotane 
were initiated. Mitotane (Sigma-Aldrich, Zwijndrecht, the 
Netherlands) was dissolved in absolute ethanol and stored at 
a concentrated stock solution (10–2 M) at –20°C, and diluted 
in ethanol prior to use. After 3 days of incubation, media and 
mitotane were refreshed. After 7 days, media were removed 
and plates and media were stored at –20°C until analysis. 
Plated cells were routinely monitored to ascertain absence 
of fibroblast contamination. By using this method and when 
considering a minimum specimen size (2 × 2  cm) with suf-
ficient viable tissue, the success percentage for obtaining a 
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primary ACC culture is >95%. To determine in vitro cortisol 
production, cortisol was measured in the media of all ACC 
using a chemiluminescence immunoassay system (Immulite 
2000XPi). Total DNA per well, reflecting the cell amount, was 
determined using the bisbenzimide fluorescent dye (Hoechst 
33258, Sigma-Aldrich), as previously described (19).
Real-time quantitative PCR
In primary cultures where ACC cells remained after isola-
tion and plating for the cell culture experiments, CYP11B1 
and STAR mRNA expression levels were measured. RRM1, 
SOAT1, and CYP2W1 mRNA expression levels were measured 
in NAs, ACAs, and ACCs. RNA isolation, cDNA synthesis and 
RT-PCR were performed as previously described, but using 
other primers (Supplementary Table 1 (20); Sigma-Aldrich) 
(21). The Vandesompele method was used to normalize the 
mRNA expression levels according to three housekeeping 
genes (22): hypoxanthine-guanine phosphoribosyl transferase 
1 (HPRT1; Sigma-Aldrich, Zwijndrecht, the Netherlands), 
Beta-actin (B-actin; Thermo Fisher Scientific, Breda, the 
Netherlands), and glucuronidase beta (GUSB; Thermo Fisher 
Scientific, Breda, the Netherlands).
RRM1, SOAT1, and Chromogranin A immuno- 
histochemistry
Construction of the TMA and immunohistochemistry of 
RRM1 and SOAT1 was performed as previously described in 
detail (23). The rabbit monoclonal RRM1 antibody (dilution 
1:50; ab135383; Abcam, Cambridge, UK), the mouse mono-
clonal SOAT1 antibody (mAb; dilution 1:1000; Sc69836; 
Santa Cruz Biotechnology, Heidelberg, Germany), and the 
rabbit polyclonal SOAT1 antibody (PoAb; dilution 1:500; 
Ab39327 (11); Abcam) were used. Blinded for the tissue 
type, the sections were independently scored by two investi-
gators (SGC, LJH) using a semi-quantitative well-established 
Immunoreactivity Score (IRS), which consists of the product of 
the percentage positive cells (4, >80%; 3, >51–80%; 2, >10%; 
1, 0) and intensity of staining (3, strong; 2, moderate; 1, mild; 
0, no staining) (24). Chromogranin A immunohistochemistry 
was performed on slides of the normal adrenal, as previously 
described (25), but using the mouse Chromogranin A primary 
antibody (LK2H10; Ventana Medical Systems).
Statistical analysis
For statistical analysis, Graphpad Prism 6.0 (Graphpad 
Software, San Diego, CA) and SPSS Statistics 21 (SPSS 21.0; 
SPSS Inc., Chicago, IL) were used. Response to mitotane was 
categorized by calculating the in vitro effect on cell amount 
at 50  µM mitotane (14  mg/L), the circulating therapeutic 
plasma concentration of mitotane (6), using nonlinear regres-
sion curve fitting. In two cases, the lowest concentration of 
mitotane caused an increase in cortisol, resulting in a top of 
the curve above 100%. When these curves were constrained 
at a top of 100%, the IC50 only minimally changed. For uni-
formity, all curves were fitted without constraint. Patient 
cultures were arbitrarily classified as nonresponder when 
the inhibitory effect on cell amount was ≤33%, as partial re-
sponders when the effect was >33% and ≤66% and responders 
showed a cell amount inhibition of >66% at 50 µM mitotane. 
Differences of categorical variables between groups were ana-
lyzed using the Fisher exact test, considering the small sample 
size. Continuous variables were compared using the Kruskal–
Wallis test or one-way ANOVA, dependent on the distribu-
tion. Overall survival was defined as the time from diagnosis 
until death or last follow-up. Response to mitotane treatment 
in vivo was assessed in patients who received mitotane within 
3 months after primary surgery. Time to relapse or progres-
sion was determined from the moment of mitotane initiation 
for patients who received mitotane as adjuvant or palliative 
treatment, respectively. Survival curves were computed using 
the Kaplan–Meier method and differences between cortisol 
and noncortisol secreting ACC were assessed by the log-rank 
(Mantel–Cox) test. A value of P < 0.05 was considered statis-
tically significant. Values are presented as mean ± SEM, unless 
specified otherwise.
Results
Patient characteristics and sensitivity to mitotane
Ten NAs, 16 ACAs, and 45 ACCs were enrolled. Patient 
and tumor characteristics are listed in Supplementary 
Table 2 (20). RRM1, SOAT1, and CYP2W1 mRNA 
expression were assessed in 55 adrenal specimens (8 
NAs, 10 ACAs, 37 ACCs), and RRM1 and SOAT1 
immunohistochemistry was performed in 59 tissues 
(7 NAs, 14 ACAs, 38 ACCs). A  primary culture was 
obtained from 32 ACCs, including 29 primary tumors 
and three local recurrences. Two patients received 
mitotane preoperatively. The first patient was treated 
with mitotane after the first recurrence, whereas the pri-
mary culture was obtained from a second recurrence. 
The second patient had stage IV disease at diagnosis and 
was treated with mitotane, which resulted in a decrease 
in the primary tumor and the lung and liver metastases. 
The metastasis in the contralateral adrenal gland how-
ever showed progression. The patient underwent surgery 
with resection of the primary tumor, the contralateral 
adrenal gland and liver metastases, and tumor tissue for 
a primary culture was obtained. All ACC patients were 
postoperatively treated with mitotane.
In human primary ACC cultures, mitotane suppressed 
cell amount and cortisol production in a dose-dependent 
fashion. The median percentage of cell amount inhib-
ition by 50 µM mitotane was 57% (IQR 39 – 71). On 
the basis of the percentage inhibition at 50 µM mitotane 
(≤33%, 33–66% or >66% inhibition), seven (22 %) 
ACCs were classified as nonresponders, 14 (44%) as 
partial responders, and 11 (34%) as responders (Table 1; 
Fig. 1, A and C–E). The mean EC50 value on cell growth 
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could not be calculated for nonresponders, because the 
dose–response curves did not reach the bottom. Fifteen 
of the 32 primary ACC cultures secreted cortisol in 
vitro. The mean EC50 of mitotane for inhibition of cor-
tisol production, corrected for cell amount, was 15 µM 
for the single cortisol producing nonresponder (Fig. 1F; 
n = 1, 14%), 1.7 µM (95% CI 1.2 – 2.5; P < 0.0001 vs 
nonresponders) for partial responders (Fig. 1G; n = 6, 
43%), and 0.90 µM (95% CI 0.69 – 1.2; P < 0.0001 vs 
nonresponders and partial responders) for responders 
(Fig. 1H; n = 8, 73%). In 14 of the 15 primary cultures 
with in vitro cortisol production, cortisol production 
was inhibited at significantly lower concentrations than 
the cell amount (Fig. 1, F–H; all P < 0.01).
In all of the ACC samples in which CYP11B1 and 
STAR mRNA was measured (n = 13), STAR mRNA 
was expressed, although in one nonresponder sample 
at a very low level (Supplementary Fig. 1 (20)). 
CYP11B1 mRNA could be detected in 12 of the 13 
ACC samples. This confirms adrenocortical origin of 
the plated cells.
Correlation of sensitivity to mitotane in vitro 
with clinical parameters
Patient and tumor characteristics of the ACCs of which a 
primary culture was obtained are listed in Table 1. There 
were differences in age at diagnosis between the three 
groups (P = 0.003); however, we did not find a linear cor-
relation. In 81% of primary cultures, in vitro and in vivo 
cortisol production were concordant. The percentage in 
vitro cortisol-producing ACC gradually increased with 
a stronger response to mitotane in vitro, ie, 14%, 43%, 
and 73% for nonresponders, partial responders, and re-
sponders, respectively (P = 0.068; Fig. 1B, Table 1). The 
same difference was observed for in vivo glucocorticoid 
secretion (P = 0.068). There were no differences in patho-
logical characteristics, tumor size, and ENSAT stage, be-
tween the three groups. A decreased overall survival was 
found for cortisol versus noncortisol secreting ACC in 
vivo (log rank P = 0.043, n = 45). Although all patients 
were treated with mitotane post surgery, evidence for a 
correlation between in vitro and in vivo mitotane sensi-
tivity is yet inconclusive, considering the heterogeneous 
Table 1. Patient and tumor characteristics for the total group of adrenocortical carcinoma patients from which a primary culture was obtaineda
Total group (ACC) Nonresponders
Partial  
responders Responders P-value
n (%) 32 7 (22) 14 (44) 11 (34)  
% cell amount inhibition at 
50 µM (median, IQR)
57 (39–71) 15 (0.0–21) 53 (44–60) 75 (70–82) <0.001
EC50 (µM, 95% CI) cell amount – > 100 µM 41.6 (33.5–51.8) 14.2 (11.3–17.9)  
EC50 (µM, 95% CI) cortisol 1.4 (0.90 – 2.1) 15 (3.2 – 75) 1.7 (1.2 – 2.5) 0.90 (0.69 – 1.2) <0.0001
n = 15 n = 1 n = 6 n = 8
Age at diagnosis (median, 
IQR, yrs)
51 (43–57) 52 (45– 65) 43 (38 – 51) 57 (52 – 70) 0.003
Male, n (%) 17 (53) 2 (29) 9 (64) 6 (55) 0.317
ENSAT staging, n (%)     0.375
I 1 (4) 0 (0) 0 (0) 1 (9)  
II 13 (46) 5 (71) 5 (42) 3 (33)  
III 2 (7) 0 (0) 2 (17) 0 (0)  
IV 13 (41) 2 (29) 5 (42) 6 (60)  
Weiss score (median, IQR) 6.0 (5.0–7.0) 6.0 (4.8–7.0) 6.0 (5.0–7.0) 7.0 (6.0–7.5) 0.372
n = 24 n = 6 n = 8 n = 9
VSI (median, IQR) 22.2 (18.9–25.1) 21.0 (16.1–25.1) 22.0 (18.3–25.3) 24.7 (19.6–28.4) 0.176
n = 30 n = 7 n = 14 n = 10
Tumor diameter (median, IQR) 14.0 (8.25–19.0) 18.0 (14.0–19.0) 11.0 (6.75–18.25) 14.0 (8.00–21.0) 0.316
In vivo secretion, n (%)      
Androgens 5 (16) 1 (14) 2 (14) 2 (18) 1.000
Cortisol 15 (47) 1 (14) 6 (43) 8 (73) 0.068
Mineralocorticoids 1 (3) 0 (0) 1 (7) 0 (0) 1.000
Precursors 2 (6) 1 (14) 1 (7) 0 (0) 0.690
Estradiol 2 (6) 0 (0) 1 (7) 1 (9) 1.000
Non secreting 13 (41) 4 (57) 6 (43) 3 (27) 0.475
In vitro cortisol secretion, n (%) 15 (47) 1 (14) 6 (43) 8 (73) 0.068
Metastasis during follow-up, n (%) 20 (63) 3 (43) 8 (57) 9 (82) 0.185
aVan Slooten Index and Weiss Score were not available for all patients, dependent on the year of diagnosis. P-value represents overall differences between the three 
groups. Significant P-values are shown in bold. Values represent mean ± SD. Nonresponders, ≤33% inhibition of cell amount at 50 µM mitotane; partial responders, 
>33% and ≤67% inhibition of cell amount at 50 µM mitotane; responders, >67% inhibition of cell amount at 50 µM mitotane. Abbreviations: CI, Confidence Interval; 
ENSAT, European Network for the Study of Adrenal Tumors, only for primary tumors; IQR, interquartile range; VSI, Van Slooten Index; yrs, years.
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patient groups, the different indications for mitotane 
treatment and the small sample size. The clinical char-
acteristics regarding in vivo mitotane sensitivity for the 
different groups can be found in Supplementary Table 3 
and Supplementary Fig. 2.
RRM1, CYP2W1, and SOAT1 mRNA expression in 
adrenal tissues and correlation with sensitivity 
to mitotane in vitro
mRNA expression levels of RRM1 and SOAT1 were 
significantly lower in ACCs than in ACAs (Fig. 2, A and 
B; P  <  0.05, P  <  0.01, respectively), whereas expres-
sion of CYP2W1 was only decreased in ACCs com-
pared with normal adrenals (Fig. 2C; P < 0.05). In ACC, 
RRM1 and SOAT1 mRNA expression levels were cor-
related (P = 0.007, ρ = 0.436), whereas no correlation 
was found between these mRNA levels and CYP2W1 
mRNA expression. In ACC, SOAT1 mRNA expres-
sion appears slightly higher in cortisol-producing ACCs 
(n = 19) than in noncortisol producing ACCs (n = 18; 
P = 0.056). SOAT1 and RRM1 mRNA and protein ex-
pression were not correlated with tumor size, ENSAT 
Figure 1. Effects of mitotane on cell growth and cortisol production in primary adrenocortical carcinoma (ACC) cultures in vitro. (A) Percentage 
of inhibition of cell growth at 50 µM per primary culture and the identification of nonresponders, partial responders, and responders. (B) The 
percentage of ACCs that in vitro produce cortisol divided per group. (C–E) Dose–response curves of mitotane on cell growth in nonresponders 
(C), partial responders (D), and responders (E). (F–H) Dose–response curves of mitotane on cortisol production corrected for cell amount in 
nonresponders (F), partial responders (G), and responders (H). Vertical dotted line represents the circulating concentration, which determined the 
responder classification (50 µM). Values are depicted as mean ± SEM. Abbreviations: NR, nonresponders; PR, partial responders; R, responders.
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stage, or histopathological criteria in ACC. CYP2W1 
mRNA expression was negatively correlated with the 
VSI in ACC (P = 0.002, ρ = -0.530). No correlation was 
found with the WS.
mRNA expression levels of RRM1, SOAT1, and 
CYP2W1 were not significantly different between 
nonresponders, partial responders, and responders to 
mitotane in vitro (Fig. 2D–F). A significant negative cor-
relation was found between the percentage cell amount 
inhibition at 50 µM mitotane and CYP2W1 mRNA ex-
pression (P < 0.0281, ρ = 0.4306).
RRM1 and SOAT1 immunohistochemistry in 
adrenal tissues and correlation with response to 
mitotane in vitro
IHC of RRM1, the most frequently described potential 
predictive factor for mitotane sensitivity, revealed ex-
pression both within the cytoplasm and in the nucleus 
of human adrenocortical cells (Fig. 3F). Since the rele-
vance and exact function of expression at both local-
izations is unknown in ACC, both localizations were 
scored for immunoreactivity. Protein expression in the 
cytoplasm was significantly higher in ACCs than in 
ACAs (Fig. 3A, P  <  0.01), whereas no differences in 
nuclear staining were found between the different tissue 
entities (Fig. 3B). Cytoplasmic and nuclear RRM1 ex-
pressions were positively correlated in ACC (Fig. 3C; 
P < 0.0001, ρ = 0.5959). RRM1 protein expression was 
not correlated with mRNA expression, nor with the ef-
fect of mitotane on cell growth (Fig. 3, D and E), and 
cortisol production in vitro.
Immunoreactivity scores of SOAT1 IHC were based 
on expression levels relative to the normal adrenal cortex 
(Fig. 4A–F). Chromogranin A  expression was used to 
differentiate between adrenal medulla and cortex (Fig. 
4G–I), demonstrating that only the monoclonal SOAT1 
Ab specifically stains the adrenal cortex (Fig. 4A–C and 
G–I). Examples of SOAT1 staining, representing different 
IRS scores in ACC, are stated in Fig. 4J–R. Within ACC, 
SOAT1 protein expression by using both antibodies was 
positively correlated (Supplementary Fig. 3C; P = 0.0004, 
ρ = 0.5424). SOAT1 protein expression as assessed by 
either the PoAb or the mAb was not different between 
NAs, ACAs, and ACCs (Supplementary Fig. 3, A and B). 
SOAT1 protein expression (mAb) was negatively cor-
related with ACC tumor size (P < 0.0001, ρ = –0.550, 
n  =  38), and was significantly higher in ACC with in 
vitro cortisol production than in the ACC cultures with 
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Figure 2. RRM1 (A,D), SOAT1 (B,E), and CYP2W1 (C,F) mRNA expression in normal adrenals, adrenocortical adenomas and adrenocortical 
carcinomas (A–C), and in ACCs stratified for mitotane responsiveness in vitro (D–F). Lines represent medians. *P < 0.05, ** P < 0.01. 
Abbreviations: ACA, adrenocortical adenomas; ACC, adrenocortical carcinomas; β-actin, Beta-actin; GUSB, glucuronidase beta; HPRT1, 
hypoxanthine-guanine phosphoribosyl transferase 1; NA, normal adrenals; NR, nonresponders; PR, partial responders; R, responders; RRM1, 
ribonucleotide reductase M1; SOAT1, Sterol-O-Acyl-Transferase 1.
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no cortisol production (n  =  28; P  =  0.011). Only the 
SOAT1 expression as assessed by the mAb was posi-
tively correlated with SOAT1 mRNA expression in ACC 
(Supplementary Fig. 3D; P = 0.0001, ρ = 0.6208), where 
the correlation with expression as assessed by the PoAb 
did not reach significance (P = 0.057, ρ = 0.334). No dif-
ference was found in SOAT1 protein expression between 
nonresponders, partial responders, and responders 
(Supplementary Fig. 3E and F). Although within a group 
of only 14 ACC, SOAT1 protein expression, as assessed 
with the mAb, was inversely correlated with the EC50 
of mitotane on cortisol production in primary cultures 
(Supplementary Fig. 3G; P = 0.0025, ρ = -0.743, n = 14). 
This indicates that higher expression of SOAT1 results 
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Figure 3. RRM1 protein expression in human adrenal specimens in the cytoplasm (A) and nucleus (B), and correlation of expression at both 
localizations in adrenocortical carcinoma (C). RRM1 protein expression in the cytoplasm (D), and nucleus (E) in adrenocortical carcinomas 
stratified for mitotane response in primary cultures. (F) Representative example of RRM1 immunohistochemical staining in the cytoplasm (left) 
and the nucleus (right) in adrenocortical carcinoma, with corresponding HE section. Sections were blinded and independently evaluated by two 
investigators. Microscopic magnification 40x, and 400x. ρ represents Spearman's rank correlation coefficient. Lines represent medians. ** P < 0.01. 
Abbreviations: ACA, adrenocortical adenomas; ACC, adrenocortical carcinomas; HE, Hematoxylin eosin; IRS, immunoreactivity score; NA, normal 
adrenals; NR, nonresponders; PR, partial responders; R, responders; RRM1, ribonucleotide reductase large subunit.
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in increased sensitivity to mitotane in vitro. This correl-
ation appeared to be a trend using the PoAb (P = 0.056, 
ρ = -0.521, n = 14). Focusing on the correlation between 
higher SOAT1 protein expression (mAb) and a stronger 
response to mitotane as defined by the percentage cell 
growth inhibition at 50 µM in primary ACC cultures, 
there was no significant correlation (Supplementary Fig. 
3H; P = 0.1201, ρ = 0.3064, n = 27).
Discussion
In this study, we demonstrate for the first time the direct 
effects of pharmacological concentrations of mitotane 
in a large series of primary human ACC cultures, 
including a correlation with clinical and tumor charac-
teristics. The general aim is to further explore potential 
predictive factors for response to mitotane.
The responder classification of ACC to mitotane 
in vitro was based on the effect on cell amount at a 
concentration of mitotane corresponding to the thera-
peutic circulating plasma concentration (14  mg/L, 
50  µM (1, 6, 7)). As a result, 34% of patients were 
classified as responder, which is consistent with clinical 
data, suggesting efficacy of mitotane in 25–35% of pa-
tients with advanced ACC (5). We also show that the 
direct antitumor effect of therapeutic concentrations of 
mitotane on growth of ACC cells is highly variable be-
tween ACC patients. Mitotane decreased cortisol pro-
duction in all cortisol-producing ACCs, and in general at 
concentrations much lower than required for inhibition 
of cell growth. This difference suggests that a measured 
inhibitory effect on cortisol in patients does not neces-
sarily resemble an antitumor effect of mitotane.
In 19% of the cases, in vivo and in vitro cortisol 
secretion were discordant. Discrepancy might be ex-
plained by tumor heterogeneity, considering that only 
a small part of the tumor is used to obtain primary 
cultures. Thereby, in a subset of ACC, tumor cells may 
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Figure 4. SOAT1 protein expression as assessed by the monoclonal and polyclonal antibody (mAb, PoAb, respectively) in human adrenal 
tissues. SOAT1 is primarily expressed in the cytoplasm (J–L). (A–I) SOAT1 and Chromogranin A (CgA, a marker for adrenal medulla) expression in 
corresponding areas in a normal adrenal. ‘S' represents stromal tissue. Right panel represents a 100× microscopic magnification of the selected 
area. (J–R) Representative sections of SOAT1 protein expression in adrenocortical carcinomas with different IRS. Microscopic magnification 40×, and 
400× in one ACC with similar IRS as determined by the mAb and the PoAb, with corresponding HE sections. Abbreviations: CgA, chromogranin A; 
HE, Hematoxylin eosin; IRS, Immunoreactivity Score.
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minimally secrete cortisol in vivo, but not sufficient 
to be diagnosed by clinical tests. The proportion of 
cortisol-producing ACC in vitro and in vivo was highest 
in the responder group, with a gradually decreasing per-
centage from the partial responder to the nonresponder 
group. Cortisol production has previously been identi-
fied as a negative prognostic factor in ACCs (26–28), 
which was confirmed in our study. Explanations for 
the decreased overall survival might be the presence of 
comorbidities associated with Cushing's syndrome and/
or the immunosuppressive effects of cortisol favoring 
tumor progression. Regarding the relation between ef-
ficacy of mitotane and cortisol production by ACCs, 
data have been inconsistent (26, 29, 30). Two more re-
cent studies have reported that mitotane treatment post 
surgery only increased disease-free survival in patients 
with cortisol-secreting tumors, whereas this was not 
seen in the whole patient group (26, 29). One of the 
possible explanations of a better response to mitotane 
in patients with cortisol-producing ACCs might be 
the decrease in cortisol secretion with concomitant 
improvement of Cushing's syndrome co-morbidities. 
However, our in vitro findings, ie, a trend towards 
more cortisol-producing ACC in the responder group, 
points towards a stronger direct antitumor effect of 
mitotane on cortisol-secreting ACC cells. It has to be 
acknowledged, however, that the group sizes are small. 
The exact mechanism of action of mitotane has yet to 
be convincingly established, although it is known that 
mitochondria-mediated intracellular stress induction 
plays a pivotal role in the basis for its action (31). The 
adrenal specificity is thought to be caused by transform-
ation of mitotane into active metabolites specifically in 
mitochondria of the adrenal gland (32). A  reasonable 
hypothesis is that cortisol-producing ACC harbor in-
creased mitochondrial function, considering the pres-
ence of a least three mitochondrial cytochrome P450s 
required for steroid synthesis (CYP11A1, CYP11B1, 
and CYP11B2). This might result in increased sensitivity 
to mitotane in cortisol-producing ACC. The inhibitory 
effects of mitotane on steroidogenesis are besides the 
toxicity the result of inhibition of several enzymes ne-
cessary for cortisol and aldosterone biosynthesis, such 
as STAR, CYP11A, and CYP11B enzymes (33). It has 
also been suggested that CYP11B1 catalyzes the initial 
hydroxylation step of mitotane (34), which has however 
not been supported by a recent report by Germano et al. 
using CYP11B1 silencing during mitotane action (35).
Given the rarity of ACC, it is difficult to obtain 
large numbers of primary cultures. Although this study 
presents a relatively large unique series, an important 
already-mentioned consideration is that the groups 
are still small and statistics have to be interpreted with 
caution. A  technical challenge as it comes to primary 
cultures is potential fibroblast contamination. As most 
important step, plates were routinely monitored to ascer-
tain absence of fibroblast contamination. Additionally, 
in a subset of primary ACC cultures, CYP11B1 and 
STAR mRNA expression were measured to confirm ad-
renal origin of the plated cells.
In clinical practice, as well as in the present in 
vitro study, a great variability is observed in sensi-
tivity to mitotane between patients. Considering the 
severe adverse effects of mitotane, there is an unmet 
need for parameters that predict treatment response. 
Expression levels of several genes, such as RRM1, 
CYP2W1, and SOAT1, have been proposed for this 
purpose (9, 11, 12). This is the first study that cor-
relates these potential predictive factors with direct 
antitumor effects in primary cultures. We only found 
a significant correlation between mRNA expression 
of CYP2W1 and increased response to mitotane in 
vitro. This finding is in the opposite direction as has 
previously been described with in vivo response and 
CYP2W1 immunoreactivity (12). CYP2W1 protein 
expression was however not assessed in this study, 
because Nole and colleagues recently showed that, 
when using a more specific antibody compared with 
the antibody used by Ronchi et  al. (12), CYP2W1 
is only rarely expressed in ACC (36). Research is 
now focusing on the predictive value of CYP2W1 
polymorphisms in ACC. For RRM1 and SOAT1, add-
itionally immunohistochemistry was performed. We 
demonstrate RRM1 protein expression in both the nu-
cleus as the cytoplasm of ACC. Localization of RRM1 
protein expression is thought to be dependent on cell 
type, tissue of origin and cellular state (37). Further 
research could focus on the relevance of RRM1 ex-
pression at both localizations in ACC. No correlations 
were observed of RRM1 protein expression and in 
vitro mitotane sensitivity. SOAT1 IHC was performed 
with the polyclonal antibody that was used by Sbiera 
et al. (11), and furthermore by using a mouse mono-
clonal antibody (Sc69836; Santa Cruz Biotechnology). 
Protein expressions as assessed by both antibodies were 
correlated in ACC, but only the expression as assessed 
using the mAb was correlated with SOAT1 mRNA ex-
pression in ACC. Thereby, in contrast to the SOAT1 
PoAb, the SOAT1 mAb showed convincing specificity 
for the adrenal cortex by comparing its expression to 
expression of chromogranin A. Chromogranin A is a 
peptide produced by chromaffin cells localized in the 
adrenal medulla (38). Together, these data suggest that 
the mouse monoclonal antibody used in this study 
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might be a more reliable antibody for determining 
SOAT1 protein expression in ACC. The trend towards 
higher SOAT1 protein expression (with mAb) in pa-
tients with a stronger response to mitotane in primary 
cultures on cortisol production is in concordance with 
previously published in vivo data showing a prolonged 
progression-free survival in patients with high SOAT1 
protein expression, although they used the PoAb (11). 
SOAT1 has an important role in cholesterol ester for-
mation in the adrenal gland, which protects adrenal 
cells from potentially damaging effects of free chol-
esterol (39, 40). Sbiera and colleagues showed that 
mitotane inhibits SOAT1 expression, which leads 
to accumulation of toxic lipids that trigger endo-
plasmic reticulum stress (11). The increased mitotane 
response in patients with high SOAT1 expression 
might be explained by the fact that SOAT1 expres-
sion is a prerequisite for mitotane efficacy (11). Given 
the potential increased SOAT1 expression in cortisol-
secreting ACC, this might be an additional explanation 
for increased direct antitumor effects of mitotane in 
cortisol-secreting ACC, although we did not show this 
in our in vitro study. Unfortunately, due to the lack of 
available mitotane serum levels in a subgroup of pa-
tients, and the diversity amongst the group of ACC pa-
tients regarding the indication for mitotane treatment 
(adjuvant or palliative), no correlations could be made 
with in vivo mitotane response. Further research is 
needed, therefore, to elucidate the predictive value of 
SOAT1 expression for mitotane response in patients 
with ACC. Furthermore, future studies could investi-
gate whether factors that have currently been associ-
ated with prognosis in ACC, like CTNNB1 and TP53 
mutations, Ki67, SF-1, Fascin-1, also correlate with 
mitotane sensitivity in vivo and in vitro (5, 14–16).
In conclusion, direct antitumor effects of mitotane on 
primary ACC cultures are highly variable between pa-
tients and inhibitory effects on cortisol production seem 
to occur at considerably lower concentrations than the 
effects on cell amount. Cortisol secretion by ACC might 
be associated with enhanced mitotane sensitivity as a 
result of increased direct antitumor effects of mitotane, 
but needs to be confirmed in further studies. Further re-
search should be performed to elucidate the relation be-
tween RRM1, SOAT1, and CYP2W1 expression, and 
mitotane sensitivity, taking into account the potential 
advantages of the monoclonal SOAT1 antibody.
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